Description:
PHENYLKETONURIA
CYSTATHIONINE GAMMA-LYASE; CTH
CYSTATHIONINURIA
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases |
Class |
Disorders of Amino Acid Metabolism |
Quantity |
25 µg |
Quantitation Method |
Please see our FAQ |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
DNA from LCL
|
Race
|
White
|
Family Member
|
1
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization after cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase Isoenzyme Electrophoresis |
|
Gene |
PAH |
Chromosomal Location |
12q24.1 |
Allelic Variant 1 |
R252Q; PHENYLKETONURIA |
Identified Mutation |
ARG252GLN |
|
Gene |
CTH |
Chromosomal Location |
1p31.1 |
Allelic Variant 1 |
607657.0003; CYSTATHIONINURIA |
Identified Mutation |
THR67ILE |
|
Gene |
CTH |
Chromosomal Location |
1p31.1 |
Allelic Variant 2 |
607657.0003; CYSTATHIONINURIA |
Identified Mutation |
THR67ILE |
|
Gene |
PAH |
Chromosomal Location |
12q24.1 |
Allelic Variant 2 |
261600.0001; PHENYLKETONURIA |
Identified Mutation |
IVS12DS, G>A, +1 (c.1315+1 G>A); The first PKU mutation identified in the PAH gene was a single base change (GT-to-AT) in the canonical 5-prime splice donor site of intron 12 (DiLella et al., 1986). Direct hybridization analysis using specific oligonucleotide probes demonstrated tight association with a specific RFLP haplotype called haplotype 3. The splicing mutation was the most prevalent PKU allele among Caucasians. Marvit et al. (1987) found that the GT-to-AT substitution at the 5-prime splice donor site of intron 12 resulted in the skipping of the preceding exon during RNA splicing. cDNA clones had shown an internal 116-basepair deletion corresponding precisely to exon 12 and leading to the synthesis of the truncated protein lacking the C-terminal 52 amino acids. Gene transfer and expression studies using the mutant PAH cDNA indicated that the deletion abolished PAH activity in the cell as a result of protein instability. The studies of Marvit et al. (1987) indicated that in fact a single nucleotide substitution rather than a deletion was the basis of the abnormal gene product.
|
Remarks |
Also has cystathioninuria; donor subject is a compound heterozygote: one allele has a pathogenic G>A transition at nucleotide 755 in exon 7 of the PAH gene [755G>A] resulting in a substitution of glutamine for arginine at codon 252 [Arg252Gln (R252Q)] and a second allele on exon 12 has a pathogenic splice site mutation at nucleotide 1315, c.1315+1G>A [IVS12+1G>A]; HLA type A28,Aw24,B7,Bw35; donor subject is also homozygous for a C>T transition at nucleotide 356 in exon 2 of the CTH gene (356C>T) resulting in the substitution of isoleucine for threonine at codon 67 [Thr67Ile (T67I)] |
Veleva D, Ay M, Ovchinnikov DA, Prowse ABJ, Menezes MJ, Nafisinia M, Generation of two lymphoblastoid-derived induced pluripotent stem cell (iPSC) lines from patients with phenylketonuria Stem cell research77:103407 2024 |
PubMed ID: 38552357 |
|
Wang J, Hegele RA, Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Hum Genet112(4):404-8 2003 |
PubMed ID: 12574942 |
|
|